Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Infectious Diseases and Therapy
Published in: Infectious Diseases and Therapy 1/2018

Open Access 01-03-2018 | Review

Challenges and Solution of Invasive Aspergillosis in Non-neutropenic Patients: A Review

Authors: Matteo Bassetti, Maddalena Peghin, Antonio Vena

Published in: Infectious Diseases and Therapy | Issue 1/2018

Login to get access

Abstract

Invasive aspergillosis (IA) is a serious opportunistic infection, which has increasingly been recognized as an emerging disease of non-neutropenic patients. In this group of patients, the diagnosis of IA can be challenging owing to the lack of specificity of symptoms, the difficulty in discriminating colonization from infection, and the lower sensitivity of microbiological and radiological tests compared with immunocompromised patients. The aim of this article is to present to clinicians a critical review on the management of IA in non-neutropenic patients.
Literature
1.
Garcia-Vidal C, Peghin M, Cervera C, et al. Causes of death in a contemporary cohort of patients with invasive aspergillosis. PLoS One. 2015;10:e0120370.CrossRefPubMedPubMedCentral
2.
Meersseman W, Vandecasteele SJ, Wilmer A, et al. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004;170:621–5.CrossRefPubMed
3.
Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and non-neutropenic patients: a 6-year survey. Clin Infect Dis. 2006;43:577–84.CrossRefPubMed
4.
5.
Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63:e1–60.CrossRefPubMedPubMedCentral
6.
Meersseman W, Lagrou K, Maertens J, et al. Invasive aspergillosis in the intensive care unit. Clin Infect Dis. 2007;45:205–16.CrossRefPubMed
7.
Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis. 2010;50:1559–67.CrossRefPubMedPubMedCentral
8.
Koulenti D, Vogelaers D, Blot S. What’s new in invasive pulmonary aspergillosis in the critically ill. Intensive Care Med. 2014;40:723–6.CrossRefPubMed
9.
Taccone FS, Van den Abeele AM, Bulpa P, et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care. 2015;19:7.CrossRefPubMedPubMedCentral
10.
Segal BH, Romani LR. Invasive aspergillosis in chronic granulomatous disease. Med Mycol. 2009;47(Suppl 1):S282–90.CrossRefPubMed
11.
De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.CrossRefPubMedPubMedCentral
12.
Blot SI, Taccone FS, Van den Abeele AM, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186:56–64.CrossRefPubMed
13.
Munoz P, Vena A, Ceron I, et al. Invasive pulmonary aspergillosis in heart transplant recipients: two radiologic patterns with a different prognosis. J Heart Lung Transplant. 2014;33:1034–40.CrossRefPubMed
14.
Prattes J, Hoenigl M, Krause R, et al. Invasive aspergillosis in patients with underlying liver cirrhosis: a prospective cohort study. Med Mycol. 2017;55(8):803–12.CrossRefPubMed
15.
Olaechea Astigarraga PM, Alvarez Lerma F. Zaldibar Enriquez E [Invasive pulmonary aspergillosis in the non-neutropenic critical patient: future challenges]. Med Intensiva. 2006;30:386–91.CrossRefPubMed
16.
Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760–9.CrossRefPubMed
17.
Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162:81–9.CrossRefPubMed
18.
Bassetti M, Bouza E. Invasive mould infections in the ICU setting: complexities and solutions. J Antimicrob Chemother. 2017;72:i39–47.CrossRefPubMed
19.
Bretagne S, Marmorat-Khuong A, Kuentz M, et al. Serum Aspergillus galactomannan antigen testing by sandwich ELISA: practical use in neutropenic patients. J Infect. 1997;35:7–15.CrossRefPubMed
20.
Maertens J, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97:1604–10.CrossRefPubMed
21.
Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42:1417–27.CrossRefPubMed
22.
Zhou W, Li H, Zhang Y, et al. Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with nonneutropenic invasive pulmonary aspergillosis. J Clin Microbiol. 2017;55:2153–61.CrossRefPubMedPubMedCentral
23.
Guinea J, Bouza E. Current challenges in the microbiological diagnosis of invasive aspergillosis. Mycopathologia. 2014;178:403–16.CrossRefPubMed
24.
Mikulska M, Furfaro E, Viscoli C. Non-cultural methods for the diagnosis of invasive fungal disease. Expert Rev Anti Infect Ther. 2015;13:103–17.CrossRefPubMed
25.
Oz Y, Aslan M, Aksit F, et al. The effect of clinical characteristics on the performance of galactomannan and PCR for the diagnosis of invasive aspergillosis in febrile neutropenic patients. Mycoses. 2016;59:86–92.CrossRefPubMed
26.
Kovanda LL, Kolamunnage-Dona R, Neely M, et al. Pharmacodynamics of isavuconazole for invasive mold disease: role of galactomannan for real-time monitoring of therapeutic response. Clin Infect Dis. 2017;64:1557–63.CrossRefPubMedPubMedCentral
27.
Neofytos D, Railkar R, Mullane KM, et al. Correlation between circulating fungal biomarkers and clinical outcome in invasive aspergillosis. PLoS ONE. 2015;10:e0129022.CrossRefPubMedPubMedCentral
28.
Chai LY, Kullberg BJ, Johnson EM, et al. Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol. 2012;50:2330–6.CrossRefPubMedPubMedCentral
29.
Russo A, Giuliano S, Vena A, et al. Predictors of mortality in non-neutropenic patients with invasive pulmonary aspergillosis: does galactomannan have a role? Diagn Microbiol Infect Dis. 2014;80:83–6.CrossRefPubMed
30.
Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al. beta-d-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52:750–70.CrossRefPubMed
31.
Lu Y, Chen YQ, Guo YL, et al. Diagnosis of invasive fungal disease using serum (1– > 3)-beta-d-glucan: a bivariate meta-analysis. Intern Med. 2011;50:2783–91.CrossRefPubMed
32.
Lamoth F, Cruciani M, Mengoli C, et al. Beta-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54:633–43.CrossRefPubMed
33.
Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum 1,3-beta-d-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol. 2012;50:7–15.CrossRefPubMedPubMedCentral
34.
Maertens JA, Blennow O, Duarte RF, et al. The current management landscape: aspergillosis. J Antimicrob Chemother. 2016;71:23–9.CrossRef
35.
Theel ES, Jespersen DJ, Iqbal S, et al. Detection of (1, 3)-beta-d-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts. Mycopathologia. 2013;175:33–41.CrossRefPubMed
36.
37.
Arvanitis M, Ziakas PD, Zacharioudakis IM, et al. PCR in diagnosis of invasive aspergillosis: a meta-analysis of diagnostic performance. J Clin Microbiol. 2014;52:3731–42.CrossRefPubMedPubMedCentral
38.
White PL, Barnes RA, Springer J, et al. Clinical performance of Aspergillus PCR for testing serum and plasma: a study by the European Aspergillus PCR initiative. J Clin Microbiol. 2015;53:2832–7.CrossRefPubMedPubMedCentral
39.
Loeffler J, Mengoli C, Springer J, et al. Analytical comparison of in vitro-spiked human serum and plasma for PCR-based detection of Aspergillus fumigatus DNA: a study by the European Aspergillus PCR initiative. J Clin Microbiol. 2015;53:2838–45.CrossRefPubMedPubMedCentral
40.
Springer J, Morton CO, Perry M, et al. Multicenter comparison of serum and whole-blood specimens for detection of Aspergillus DNA in high-risk hematological patients. J Clin Microbiol. 2013;51:1445–50.CrossRefPubMedPubMedCentral
41.
Springer J, White PL, Hamilton S, et al. Comparison of performance characteristics of Aspergillus PCR in testing a range of blood-based samples in accordance with international methodological recommendations. J Clin Microbiol. 2016;54:705–11.CrossRefPubMedPubMedCentral
42.
Mengoli C, Cruciani M, Barnes RA, et al. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:89–96.CrossRefPubMed
43.
Imbert S, Gauthier L, Joly I, et al. Aspergillus PCR in serum for the diagnosis, follow-up and prognosis of invasive aspergillosis in neutropenic and nonneutropenic patients. Clin Microbiol Infect. 2016;22(562):e1–8.
44.
Chong GL, van de Sande WW, Dingemans GJ, et al. Validation of a new Aspergillus real-time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid. J Clin Microbiol. 2015;53:868–74.CrossRefPubMedPubMedCentral
45.
Held J, Schmidt T, Thornton CR, et al. Comparison of a novel Aspergillus lateral-flow device and the Platelia(R) galactomannan assay for the diagnosis of invasive aspergillosis following haematopoietic stem cell transplantation. Infection. 2013;41:1163–9.CrossRefPubMed
46.
Willinger B, Lackner M, Lass-Florl C, et al. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis in solid organ transplant patients: a semiprospective multicenter study. Transplantation. 2014;98:898–902.CrossRefPubMed
47.
Prattes J, Flick H, Pruller F, et al. Novel tests for diagnosis of invasive aspergillosis in patients with underlying respiratory diseases. Am J Respir Crit Care Med. 2014;190:922–9.CrossRefPubMed
48.
Eigl S, Prattes J, Lackner M, et al. Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients. Crit Care. 2015;19:178.CrossRefPubMedPubMedCentral
49.
de Heer K, van der Schee MP, Zwinderman K, et al. Electronic nose technology for detection of invasive pulmonary aspergillosis in prolonged chemotherapy-induced neutropenia: a proof-of-principle study. J Clin Microbiol. 2013;51:1490–5.CrossRefPubMedPubMedCentral
50.
Koo S, Thomas HR, Daniels SD, et al. A breath fungal secondary metabolite signature to diagnose invasive aspergillosis. Clin Infect Dis. 2014;59:1733–40.CrossRefPubMedPubMedCentral
51.
Domingo MP, Colmenarejo C, Martinez-Lostao L, et al. Bis(methyl)gliotoxin proves to be a more stable and reliable marker for invasive aspergillosis than gliotoxin and suitable for use in diagnosis. Diagn Microbiol Infect Dis. 2012;73:57–64.CrossRefPubMed
52.
Vidal-Garcia M, Domingo MP, De Rueda B, et al. Clinical validity of bis(methylthio)gliotoxin for the diagnosis of invasive aspergillosis. Appl Microbiol Biotechnol. 2016;100:2327–34.CrossRefPubMed
53.
Dai Z, Zhao H, Cai S, et al. Invasive pulmonary aspergillosis in non-neutropenic patients with and without underlying disease: a single-centre retrospective analysis of 52 subjects. Respirology. 2013;18:323–31.CrossRefPubMed
54.
Henzler C, Henzler T, Buchheidt D, et al. Diagnostic performance of contrast enhanced pulmonary computed tomography angiography for the detection of angioinvasive pulmonary aspergillosis in immunocompromised patients. Sci Rep. 2017;7:4483.CrossRefPubMedPubMedCentral
55.
Bassetti M, Carnelutti A, Muser D, et al. 18F-fluorodeoxyglucose positron emission tomography and infectious diseases: current applications and future perspectives. Curr Opin Infect Dis. 2017;30:192–200.CrossRefPubMed
56.
Kim JY, Yoo JW, Oh M, et al. (18)F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography findings are different between invasive and noninvasive pulmonary aspergillosis. J Comput Assist Tomogr. 2013;37:596–601.CrossRefPubMed
57.
Hot A, Maunoury C, Poiree S, et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect. 2011;17:409–17.CrossRefPubMed
58.
Rolle AM, Hasenberg M, Thornton CR, et al. ImmunoPET/MR imaging allows specific detection of Aspergillus fumigatus lung infection in vivo. Proc Natl Acad Sci USA. 2016;113:E1026–33.CrossRefPubMedPubMedCentral
59.
Marr KA. Empirical antifungal therapy—new options, new tradeoffs. N Engl J Med. 2002;346:278–80.CrossRefPubMed
60.
Cornely OA, Meems L, Herbrecht R, et al. Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. Mycoses. 2015;58:58–64.CrossRefPubMed
61.
Cattaneo C, Monte S, Algarotti A, et al. A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study). J Antimicrob Chemother. 2011;66:2140–5.CrossRefPubMed
62.
Hiemenz JW, Raad II, Maertens JA, et al. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis. 2010;29:1387–94.CrossRefPubMed
63.
Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–15.CrossRefPubMed
64.
Ledoux MP, Toussaint E, Denis J, et al. New pharmacological opportunities for the treatment of invasive mould diseases. J Antimicrob Chemother. 2017;72:i48–58.CrossRefPubMed
65.
Baddley JW, Stephens JM, Ji X, et al. Aspergillosis in intensive care unit (ICU) patients: epidemiology and economic outcomes. BMC Infect Dis. 2013;13:29.CrossRefPubMedPubMedCentral
66.
Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis. 2015;61:1558–65.CrossRefPubMed
67.
Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44:1289–97.CrossRefPubMed
68.
Altini C, Niccoli Asabella A, Ferrari C, et al. (18)F-FDG PET/CT contribution to diagnosis and treatment response of rhino-orbital-cerebral mucormycosis. Hell J Nucl Med. 2015;18:68–70.PubMed
Metadata
Title
Challenges and Solution of Invasive Aspergillosis in Non-neutropenic Patients: A Review
Authors
Matteo Bassetti
Maddalena Peghin
Antonio Vena
Publication date
01-03-2018
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 1/2018
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-017-0183-9

Other articles of this Issue 1/2018

Infectious Diseases and Therapy 1/2018 Go to the issue

Review

Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review

Original Research

Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants

Review

Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children

Review

Who Is the Patient at Risk of CMV Recurrence: A Review of the Current Scientific Evidence with a Focus on Hematopoietic Cell Transplantation

Brief Report

Geographic Variability in Diagnosis and Antibiotic Prescribing for Acute Respiratory Tract Infections

Original Research

Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits